Anker Lundemose is appointed chairman of the board

February 8 – 2023

Anker Lundemose is appointed chairman of the board

Commit welcomes Anker Lundemose as executive chairman of the board. MD, PhD Anker Lundemose is CEO at Mission Therapeutics (backed by Sofinnova Partners, Roche Venture Fund, Pfizer Ventures and SR One) and has held numerous management and board positions in high-profile biotech companies. With extensive experience in business development, corporate development, M&A strategy and execution, financing as well as R&D, Anker will help set the direction and shape the future of Commit biologics.

More news

See all news

October 15 – 2024

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Employees Events

Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement. Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing. Dr Pedersen will spearhead research and development of …

June 10 – 2024

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

Events News

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform Aarhus, …

May 9 – 2024

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

Funding News

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) …

For inquiries please contact us
at info@commitbio.com

Commit Biologics ApS
Universitetsbyen 83
8000 Aarhus C, Denmark

+45 3049 7099
LinkedIn